Related Experiment Video
Updated: Aug 2, 2026

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Association of GSDMD with microvascular-ischemia reperfusion injury after ST-elevation myocardial infarction
Wenjing Sun1,2, Chunqiu Wang3, Shihua Cui4
1Department of Cardiology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, China.
Objectives:
Little is known about the clinical prognosis of gasdermin D (GSDMD) in patients with ST-elevation myocardial infarction (STEMI). The purpose of this study was to investigate the association of GSDMD with microvascular injury, infarction size (IS), left ventricular ejection fraction (LVEF), and major adverse cardiac events (MACEs), in STEMI patients with primary percutaneous coronary intervention (pPCI).
Methods:
We retrospectively analyzed 120 prospectively enrolled STEMI patients (median age 53 years, 80% men) treated with pPCI between 2020 and 2021 who underwent serum GSDMD assessment and cardiac magnetic resonance (CMR) within 48 h post-reperfusion; CMR was also performed at one year follow-up.
Results:
Microvascular obstruction was observed in 37 patients (31%). GSDMD concentrations ≧ median (13 ng/L) in patients were associated with a higher risk of microvascular obstruction and IMH (46% vs. 19%, P = 0.003; 31% vs. 13%, P = 0.02, respectively), as well as with a lower LVEF both in the acute phase after infarction (35% vs. 54%, P < 0.001) and in the chronic phase (42% vs. 56%, P < 0.001), larger IS in the acute (32% vs. 15%, P < 0.001) and in the chronic phases (26% vs. 11%, P < 0.001), and larger left ventricular volumes (119 ± 20 vs. 98 ± 14, P = 0.003) by CMR. Univariable and multivariable Cox regression analysis results showed that patients with GSDMD concentrations ≧ median (13 ng/L) had a higher incidence of MACE (P < 0.05).
Conclusions:
High GSDMD concentrations in STEMI patients are associated with microvascular injury (including MVO and IMH), which is a powerful MACE predictor. Nevertheless, the therapeutic implications of this relation need further research.
Insights
High gasdermin D (GSDMD) levels in ST-elevation myocardial infarction (STEMI) patients correlate with microvascular injury and predict major adverse cardiac events (MACE). Further research is needed to explore therapeutic implications.
Area of Science:
- Cardiology
- Molecular Medicine
- Biomarker Research
Background:
- Gasdermin D (GSDMD) role in ST-elevation myocardial infarction (STEMI) prognosis is largely unknown.
- Understanding GSDMD's impact on cardiac injury and outcomes is crucial for STEMI management.
Purpose of the Study:
- To investigate the association between GSDMD levels and microvascular injury, infarction size (IS), left ventricular ejection fraction (LVEF), and major adverse cardiac events (MACE).
- To evaluate GSDMD as a prognostic marker in STEMI patients undergoing primary percutaneous coronary intervention (pPCI).
Main Methods:
- Retrospective analysis of 120 STEMI patients treated with pPCI.
- Serum GSDMD assessment and cardiac magnetic resonance (CMR) imaging performed within 48 hours and at one-year follow-up.
Main Results:
- Elevated GSDMD concentrations (≥ median 13 ng/L) were linked to increased microvascular obstruction and intramyocardial hemorrhage (IMH).
- Higher GSDMD levels correlated with reduced LVEF, larger IS in acute and chronic phases, and increased left ventricular volumes.
- GSDMD levels ≥ median were associated with a higher incidence of MACE.
Conclusions:
- High GSDMD concentrations in STEMI patients are significantly associated with microvascular injury, including MVO and IMH.
- GSDMD emerges as a potent predictor of MACE in STEMI.
- Further investigation is warranted to elucidate the therapeutic implications of GSDMD in STEMI management.
More Related Videos
Related Concept Videos
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Mitral Stenosis I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Aneurysm III: Interprofessional Care
Diabetic Retinopathy
Hemorrhagic Stroke ll: Pathophysiology

